Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03918499
Title IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Cyclophosphamide + IRX-2 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.